| 8/9/2024 | CVLM | Insmed only redeems $198,000 of 1.75% convertibles due 2025
|
| 6/27/2024 | CVLM | Insmed calls all $225 million 1.75% convertible notes due 2025
|
| 5/28/2024 | CV | Market Commentary: Microchip convertibles on tap; Alarm.com eyed; Alibaba dominates trading; Insmed active
|
| 8/29/2023 | CV | Market Commentary: Akamai convertible notes break par; NextEra, Insmed paper active; Coinbase gains
|
| 8/7/2023 | CV | Market Commentary: Convertible primary floodgates open; Hannon Armstrong, Fluor, Envista on deck
|
| 10/7/2021 | CV | Market Commentary: Sea surges in active trade; Square, LendingTree add with shares; Golar maturity eyed
|
| 10/7/2021 | CV | Market Commentary: Morning Commentary: Novavax convertibles trade with higher shares; Insmed notes eyed
|
| 5/13/2021 | CV | Insmed greenshoe lifts 0.75% convertibles due 2028 to $575 million
|
| 5/12/2021 | CV | Market Commentary: Fluor on tap; ON Semiconductor convertibles contract; ‘No-Nos’ under pressure; Insmed up
|
| 5/11/2021 | CV | Market Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket amid market volatility
|
| 5/11/2021 | CV | Market Commentary: Morning Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket
|
| 5/11/2021 | CVLM | Insmed to redeem $225 million of its 1.75% convertibles due 2025
|
| 5/11/2021 | CV | New Issue: Insmed sells $500 million seven-year convertible notes to yield 0.75%, up 30%
|
| 5/10/2021 | CV | Market Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax, ON Semiconductor on deck
|
| 5/10/2021 | CV | Market Commentary: Morning Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax on deck
|
| 5/10/2021 | CV | Insmed talks $500 million seven-year convertible notes to yield 0.5%-1%, up 25%-30%
|
| 2/3/2020 | CV | Market Commentary: Integra convertibles on tap; Tesla ‘a beast’; Luckin Coffee volatile; Insmed expands
|
| 2/3/2020 | CV | Market Commentary: Morning Commentary: Luckin Coffee convertible rebounds slightly; Insmed jumps outright
|
| 1/28/2020 | CV | Market Commentary: Semiconductor names eyed in convertibles market amid earnings; Insmed notes expand
|
| 6/17/2019 | CV | Market Commentary: Morning Commentary: Secondary trading light; health care sector boosted by Array buyout
|
| 5/7/2019 | CV | Market Commentary: Tesla’s new convertible notes come in; Microchip active; Insmed trades down outright
|
| 1/7/2019 | CV | Market Commentary: Convertibles secondary tone improves; Ares Capital dominates trading; biotechs strong
|
| 1/7/2019 | CV | Market Commentary: Morning Commentary: Ares Capital continues to dominate trading; biotech tape strong
|
| 12/19/2018 | CV | Market Commentary: Benefitfocus on tap; Micron drops outright, expands dollar-neutral; Insmed contracts
|
| 10/3/2018 | CV | Market Commentary: Tilray on tap; Boingo convertibles expand on debut; Apollo Commercial trades flat
|
| 10/1/2018 | CV | Market Commentary: Boingo on tap; convertibles trading light; Tesla rebounds; Insmed, Infinera contract
|
| 10/1/2018 | CV | Market Commentary: Morning Commentary: Tesla stock surges, convertibles less active; Insmed drops outright
|
| 8/14/2018 | CV | Market Commentary: FTI Consulting on tap; Microchip has its volatility event; Booking active; Insmed down
|
| 8/3/2018 | CV | Market Commentary: Convertibles space sees quiet end to week; Greenlight ‘buttoned up’; Insmed volatile
|
| 7/11/2018 | CV | Market Commentary: Sempra’s convertible preferreds trade up; Palo Alto, Twitter in focus; biotech active
|
| 5/2/2018 | CV | Market Commentary: Five9, Teladoc on tap; JPMorgan/Voya notes, IAC convertibles active; Ironwood eyed
|
| 4/23/2018 | CV | Market Commentary: JPMorgan on tap; Clovis contraction continues; Insmed improves; Ctrip.com, NXP active
|
| 4/23/2018 | CV | Market Commentary: Morning Commentary: NXP Semiconductors active in early trading; Insmed convertible notes improve
|
| 4/17/2018 | CV | Market Commentary: South Jersey, Deutsche on tap; Clovis convertibles ‘well received’; oil still catching bids
|
| 4/12/2018 | CV | Market Commentary: Transocean convertibles in focus; primary quiet; biotech sector firm; Caesars active
|
| 4/2/2018 | CV | Market Commentary: ‘Soft tape’ in convertibles space; Chegg maintains strength; recent deals below par
|
| 3/26/2018 | CV | Market Commentary: Landmark convertible preferreds on tap; Blackstone Mortgage at par; Live Nation active
|
| 3/26/2018 | CV | Market Commentary: Morning Commentary: Blackstone up to par in small-volume trades; Insmed active
|
| 2/23/2018 | CV | Market Commentary: Okta’s convertibles expand on debut; Q2 trading activity tempers; Exact Sciences lower
|
| 2/2/2018 | CV | Market Commentary: Convertibles settle down; ‘rough tape’ for recent biotech deals; Lam Research tumbles
|
| 2/2/2018 | CV | Market Commentary: Morning Commentary: Convertibles market settles down; ‘rough tape’ for recent biotech deals
|
| 2/1/2018 | CV | Market Commentary: Western Digital holds strong; recent deals still ‘licking wounds’; Shutterfly soars
|
| 1/30/2018 | CV | Market Commentary: Alder ‘getting smoked’; Western Digital deal a landmark; new paper adding pressure
|
| 1/29/2018 | CV | Market Commentary: Western Digital to price $1 billion; Alder richens deal; convert market ‘trying to absorb’ new paper
|
| 1/29/2018 | CV | Market Commentary: Morning Commentary: Alder BioPharmaceuticals to sell convertibles; market off to slow start
|
| 1/26/2018 | CV | Insmed greenshoe exercised, lifts 1.75% convertibles to $450 million
|
| 1/25/2018 | CV | Market Commentary: Senseonics, Oil States on tap; First Majestic hits market; new paper active; Nutanix drops
|
| 1/25/2018 | CV | Market Commentary: Morning Commentary: Oil States to price; First Majestic hits market; new paper active
|
| 1/24/2018 | CV | Market Commentary: First Majestic to price; Oil States on tap; Insmed dominates; ‘borrow tight’ on Teekay
|
| 1/24/2018 | CV | Market Commentary: Morning Commentary: Insmed, Teekay price new convertible notes; ‘borrow tight’ on Teekay
|
| 1/24/2018 | CV | New Issue: Insmed prices upsized $400 million seven-year convertibles to yield 1.75%, up 35%
|
| 1/23/2018 | CV | Market Commentary: Teekay eyes deal; Insmed seen as cheap; new paper active; Priceline gains on new CFO
|
| 1/23/2018 | CV | Market Commentary: Morning Commentary: Convertibles primary market awaits Insmed deal, initially seen as cheap
|
| 1/22/2018 | CV | Market Commentary: Insmed eyes deal; secondary market ‘not moving’; Exact Sciences, optic companies lose footing
|
| 1/22/2018 | CV | Insmed talks $300 million seven-year convertibles to yield 1.75% to 2.25%, up 27.5% to 32.5%
|
| 6/14/2012 | CVHYPF | Insmed files $75 million shelf for debt securities, stock, preferreds
|
| 3/1/2011 | CVLMPF | Insmed converts series B preferreds, plans reverse stock split
|
| 2/3/2006 | BTCV | Insmed files $75 million shelf
|
